Crinetics Heads Into Earnings With Shorts in Full Retreat

CRNX arrives at its August 4 earnings report in an unusual position: short sellers have dramatically unwound their bets even as the stock sits near double its price from a month ago, leaving the market more focused on deal mechanics than operational fundamentals.

The short-side retreat is the defining feature of CRNX's positioning. Short interest has collapsed by nearly half over the past month to 7% of the free float — dramatic in both speed and scale. The history tells the story clearly: shorts held around 13 million shares as recently as early July, a figure that has since been cut to roughly 6.7 million. Borrow conditions confirm the unwind rather than contradict it. Availability is exceptionally loose at roughly 1,193% — meaning the pool of shares available to lend is nearly twelve times the current short interest — and the cost to borrow has fallen to just 0.17%, down sharply from over 0.5% in June. Shorts are not pressing here; they are leaving.

The reason is unmistakable. Vertex Pharmaceuticals announced a roughly $10 billion all-cash acquisition of Crinetics, targeting the company's commercialised acromegaly therapy Palsonify — the first once-daily oral treatment in that indication — alongside its pipeline of rare endocrine disease and solid tumour candidates. The stock responded violently, rising roughly 98% over the past month to close at $83.76. Options positioning reflects neither urgency nor panic going into the print: the put/call ratio of 0.49 is essentially in line with its 20-day average of 0.51, suggesting the market is not paying a premium for protection in either direction.

Analysts have adjusted rapidly to the new reality, though the moves are nuanced. A wave of downgrades landed in early July — from Jefferies, TD Cowen, Cantor Fitzgerald, Evercore ISI, and others — but almost all of those came with target-price increases, clustering around $85. UBS downgraded from Buy to Neutral on July 28 while simultaneously lifting its target from $55 to $85. Baird held its Outperform rating and raised its target to $85 from $62. The message from the Street is consistent: the stock is now fairly priced relative to the deal value, not a broken thesis. With the mean price target at $85.50 against a current price of $83.76, there is little perceived upside beyond the transaction close. Institutional holders remain heavily committed — Fidelity at nearly 15%, BlackRock at 8%, Wellington at 7.7% — with most adding to positions through Q2.

Today's earnings print is therefore less a test of Crinetics as a standalone growth story and more an examination of deal execution confidence: any guidance on the Vertex transaction timeline, Palsonify's commercial ramp, or pipeline read-throughs will be weighed against a stock that has already priced in a near-complete premium.